Generic Trelstar Availability
Last updated on Sep 8, 2022.
TRELSTAR (triptorelin pamoate - injectable;intramuscular)
Approval date: June 15, 2000
Strength(s): EQ 3.75MG BASE/VIAL [RLD]
Approval date: June 29, 2001
Strength(s): EQ 11.25MG BASE/VIAL [RLD]
Approval date: March 10, 2010
Strength(s): EQ 22.5MG BASE/VIAL [RLD]
Has a generic version of Trelstar been approved?
No. There is currently no therapeutically equivalent version of Trelstar available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trelstar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Slow release pharmaceutical composition made of microgranules
Issued: January 1, 2019
Assignee(s): Debiopharm Research & Manufacturing SA
Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D (v,0.9) is between 50 and 1 10 micrometers.
Patent expiration dates:
- June 30, 2029✓
- June 30, 2029
More about Trelstar (triptorelin)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy
- Reviews (5)
- Drug images
- Pricing & coupons
- En español
- Drug class: gonadotropin releasing hormones
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.